MAP2K7 and non-small cell lung carcinoma: The MEK inhibitor trametinib inhibits the expression of SPRY4 in stromal-like KRAS mutant NSCLC, leading to the activation of AKT and ERK signals in stromal-like KRAS mutant lung cancer cells (29).